<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017753</url>
  </required_header>
  <id_info>
    <org_study_id>TAP-IT</org_study_id>
    <nct_id>NCT05017753</nct_id>
  </id_info>
  <brief_title>Thoracentesis to Alleviate Cardiac Pleural Effusion</brief_title>
  <acronym>TAP-IT</acronym>
  <official_title>Thoracentesis to Alleviate Cardiac Pleural Effusion - an Interventional Trial (TAP-IT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Independent Research Fund Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hartmann Fonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will examine the comparative effectiveness of two treatment strategies&#xD;
      currently used in the treatment of patients with systolic heart failure presenting with&#xD;
      pleural effusion. Patients will be randomized to standard medical treatment only or medical&#xD;
      treatment and referral to thoracentesis.&#xD;
&#xD;
      Study hypothesis: A strategy of referring patients with heart failure-related pleural&#xD;
      effusion to thoracentesis increases number of days alive outside of hospital over the&#xD;
      following 90 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose and Rationale: Pleural effusion is a common presentation in patients with heart&#xD;
      failure, and the condition is related to a poor prognosis and increased mortality.&#xD;
      Therapeutic options consist of intensification of diuretic treatment and invasive drainage of&#xD;
      the effusion (thoracentesis). Thoracentesis is a common medical procedure and is often&#xD;
      performed on patients with heart failure presenting with a pleural effusion, but there is no&#xD;
      randomized evidence to guide the use of thoracentesis in heart failure-related pleural&#xD;
      effusion. International guidelines provide no recommendations. Some Danish hospitals use&#xD;
      thoracentesis frequently, some rarely. Hence, there is true clinical equipoise and a strong&#xD;
      need to assess whether thoracentesis benefits patients or not.&#xD;
&#xD;
      Study Hypothesis: A strategy of referring patients with heart failure-related pleural&#xD;
      effusion to thoracentesis increases number of days alive outside of hospital over the&#xD;
      following 90 days.&#xD;
&#xD;
      Study Setting:126 adult patients admitted with systolic heart failure and pleural effusion&#xD;
      documented by either chest x- ray, ultrasound, computed tomography (CT) or magnetic resonance&#xD;
      imaging (MRI) will be randomized 1:1 to medical treatment only or medical treatment and&#xD;
      referral to thoracentesis. Thoracentesis will be performed according to local practice.&#xD;
      Randomization will be stratified according to whether patients are treated with oral&#xD;
      anticoagulation.&#xD;
&#xD;
      Crossover/rescue thoracentesis: For patients in the medical treatment arm whose condition&#xD;
      deteriorates to the degree that the participant fulfill any of the study exclusion criteria&#xD;
      (eg. increased need of oxygen), thoracentesis may be performed immediately. Some patients&#xD;
      randomized to medical treatment only may prove to be too diuretic resistant to achieve an&#xD;
      adequate effect of medical treatment alone. The recommended waiting period before performing&#xD;
      thoracentesis on a patient in the control group is 5 days from randomization.&#xD;
&#xD;
      Patients may be discharged at the discretion of the treating physician. The follow up period&#xD;
      is planned to 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial is a pragmatic controlled, randomized, multicenter open label trial with including patients admitted with pleural effusion related to systolic heart failure. Patients will be randomized 1:1 to standard-of-care medical treatment only or standard-of-care medical treatment and referral to thoracentesis. Randomization will be stratified according to whether patients are treated with oral anticoagulation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive outside of hospital (days)</measure>
    <time_frame>90 days</time_frame>
    <description>Number of days the patient is alive outside of hospital in the 90 days following randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with hospital stay (Likert scale)</measure>
    <time_frame>Up til 1 week after discharge</time_frame>
    <description>Selected questions from the questionnaire &quot;Questions about your admission&quot; from the annual Danish National Survey of Patient Experiences to assess satisfaction with index admission. Likert scale from 1-5. 5 represents the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ-12) (score)</measure>
    <time_frame>At 14 days and 90 days - up til 1 week</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ). Selected scores from the 12-item questionnaire, including changes in scores between 14 and 90 days. Scores from 1-100 with 100 representing the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications during hospital stay (count)</measure>
    <time_frame>From randomization until the date af discharge from hospital. Estimated time frame from 2 days to 3 weeks.</time_frame>
    <description>Number of complications during the index admission (eg. infections, delirium, falls, thrombosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications to thoracentesis (count)</measure>
    <time_frame>From randomization until the date af discharge from hospital. Estimated time frame from 2 days to 3 weeks.</time_frame>
    <description>Number of complications to interventional thoracentesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of index admission (days)</measure>
    <time_frame>From randomization until the date af discharge from hospital. Estimated time frame from 2 days to 3 weeks.</time_frame>
    <description>Duration of index admission following randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in weight during admission (kg)</measure>
    <time_frame>From randomization until the date af discharge from hospital. Estimated time frame from 2 days to 3 weeks.</time_frame>
    <description>Changes in weight during admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in dosage of diuretics during admission (mg/day)</measure>
    <time_frame>From randomization until the date af discharge from hospital. Estimated time frame from 2 days to 3 weeks.</time_frame>
    <description>Change in dosage of diuretics during index admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death (days)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first readmission or death (days)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Heart Failure</condition>
  <condition>Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard-of-care medical treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracentesis in addition to standard-of-care medical treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracentesis</intervention_name>
    <description>Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Thoracocentesis</other_name>
    <other_name>Pleurocentesis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard-of-care medical treatment</intervention_name>
    <description>Standard-of-care medical treatment</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≤ 45%&#xD;
&#xD;
          -  Non- negligible pleural effusion by x-ray, ultrasound, CT or MRI, suspected to be due&#xD;
             to heart failure&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected malignant disease&#xD;
&#xD;
          -  Suspected pulmonary or pleural infection (pneumonia symptoms with c- reactive&#xD;
             protein&gt;100 mg/L or white blood count&gt;11)&#xD;
&#xD;
          -  Recent (&lt;3 months) intrathoracic procedure (including heart or lung surgery,&#xD;
             transcatheter aortic valve implantation (TAVI) or thoracentesis)&#xD;
&#xD;
          -  Contraindications to thoracentesis according to local guidelines (such as&#xD;
             spontaneously elevated international normalized ratio (INR) or thrombocytopenia),&#xD;
             patients on oral anticoagulation may be randomized.&#xD;
&#xD;
          -  Severe aortic stenosis&#xD;
&#xD;
          -  Massive pleural effusion (equivalent to &gt;2/3 of lung on a standing chest x-ray)&#xD;
&#xD;
          -  Substantially affected hemodynamics (systolic blood pressure &lt; 85mmHg, need of&#xD;
             inotropes) or high oxygen demand (&gt;7L/min)&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;15ml/min/1.73m2 or acute renal failure&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Signe Glargaard, MD</last_name>
    <phone>61696721</phone>
    <phone_ext>+45</phone_ext>
    <email>signe.glargaard@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Jakob Thune, MD, Ph.D.</last_name>
    <phone>24428389</phone>
    <phone_ext>+45</phone_ext>
    <email>jens.jakob.thune@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Aalborg</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Aarhus</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Bispebjerg and Frederiksberg</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Rigshospitalet, Glostrup</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Herlev/Gentofte</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Nordsjaelland</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Odense</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Zealand, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Odense, Svendborg</name>
      <address>
        <city>Svendborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Jens Jakob Thune</investigator_full_name>
    <investigator_title>Clinical Research Associate Professor, Consultant Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Systolic heart failure</keyword>
  <keyword>Pleural effusion</keyword>
  <keyword>Thoracentesis</keyword>
  <keyword>Thoracocentesis</keyword>
  <keyword>Pleurocentesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

